By
Drug Target Review2023-12-12T12:00:53
The new small molecule targets the glutamate system, reducing MS-like symptoms and repairing damaged myelin in two different animal models.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-10T06:15:00Z
Contributor Professor Donald E Ingber, By Drug Target Review
2026-07-08T12:00:00Z
2026-07-07T12:00:00Z
2023-06-13T13:30:40
Sponsored by NanoTemper Technologies
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2026-03-25T15:00:00
Sponsored by Yokogawa
2026-06-24T13:00:00
Sponsored by HUB Organoids
2023-02-23T14:02:18
Sponsored by bit.bio
Site powered by Webvision Cloud